Inactivation of TGF-β signaling in lung cancer results in increased CDK4 activity that can be rescued by ELF

Biochemical and Biophysical Research Communications

Volumn 346, Issue 4, 2006, Pages 1150-1157

  Baek, Hye Jung ^a   Kim, Sang Soo ^a   da Silva, Fabio May ^a   Volpe, Eugene A ^a   Evans, Stephen ^a   Mishra, Bibhuti ^a   Mishra, Lopa ^a,b   Blair Marshall, M ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

CDK4; Cell cycle; ELF; Lung cancer

Indexed keywords

ADAPTOR PROTEIN; CYCLIN DEPENDENT KINASE 4; EMBRYONIC LIVER FODRIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CONTROLLED STUDY; HEART DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER; LUNG; LUNG CANCER; MESOTHELIOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL; WESTERN BLOTTING;

ANIMALS; CARCINOMA; CARRIER PROTEINS; CELL CYCLE; CYCLIN-DEPENDENT KINASE 4; G1 PHASE; HUMANS; LUNG NEOPLASMS; MICE; MICROFILAMENT PROTEINS; S PHASE; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 33745639683     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.05.195     Document Type: Article

References (45)

1. Landis S.H., Murray T., Bolden S., and Wingo P.A. Cancer statistics. CA Cancer J. Clin. 49 (1999) 8-31
2. Fontanini G., Faviana P., Lucchi M., Boldrini L., Mussi A., Camacci T., Mariani M.A., Angeletti C.A., Basolo F., and Pingitore R. A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. Br. J. Cancer 86 (2002) 558-563
3. Kaminska B., Wesolowska A., and Danilkiewicz M. TGF β signaling and its role in tumor pathogenesis. Acta Biochim. Pol. 52 (2005) 329-337
4. Roberts A., and Mishra L. Role of TGF-β in stem cells and cancer. Oncogene 24 (2005) 5667
5. Anumanthan G., Halder S.K., Osada H., Takahashi T., Massion P.P., Carbone D.P., and Datta P.K. Restoration of TGF-β signaling reduces tumorigenicity in human lung cancer cells. Br. J. Cancer 93 (2005) 1157-1167
6. Park C., Kim W.S., Choi Y., Kim H., and Park K. Effects of transforming growth factor β (TGF-β) receptor on lung carcinogenesis. Lung Cancer 38 (2002) 143-147
7. Mishra L., Derynck R., and Mishra B. Transforming growth factor-β signaling in stem cells and cancer. Science 310 (2005) 68-71
8. Kim W.S., Park C., Hong S.K., Park B.K., Kim H.S., and Park K. Microsatillite instability (MSI) in non-small cell lung cancer (NSCLC) is highly associated with transforming growth factor-β type II receptor (TGF-β RII) frameshift mutation. Anticancer Res. 20 (2000) 1499-1502
9. Kang Y., Ozbun L.L., Angdisen J., Moody T.W., Prentice M., Diwan B.A., and Jakowlew S.B. Altered expression of G1/S regulatory genes occurs early and frequently in lung carcinogenesis in transforming growth factor-β1 heterozygous mice. Carcinogenesis 23 (2002) 1217-1227
10. Damstrup L., Rygaard K., and Spang-Thomsen M. Expression of transforming growth factor β (TGF β) receptors and expression of TGF rbeta1, TGF β2 and TGF β3 in human small cell lung cancer cell lines. Br. J. Cancer 67 (1993) 1015-1021
11. Osada H., Tatematsu Y., Masuda A., Saito T., Sugiyama M., Yanagisawa K., and Takahashi T. Heterogeneous transforming growth factor (TGF)-β unresponsiveness and loss of TGF-β receptor type II expression caused by histone deacetylation in lung cancer cell lines. Cancer Res. 61 (2001) 8331-8339
12. Feng X.H., and Derynck R. A kinase subdomain of transforming growth factor (TGF)-β type I receptor determines the TGF-β intracellular signaling specificity. EMBO J. 16 (1997) 3912-3923
13. Kimchi A., Wang X.F., Weinberg R.A., Cheifetz S., and Massague J. Absence of TGF-β receptors and growth inhibitory responses in retinoblastoma cells. Science 240 (1988) 196-199
14. Sporn M.B. TGF-β: 20 years and counting. Microbes Infect. 1 (1999) 1251-1253
15. Massague J., Blain S.W., and Lo R.S. TGF-β signaling in growth control, cancer and heritable disorders. Cell 103 (2000) 295-309
16. Derynck R., and Zhang Y.E. Smad-dependent and Smad-independent pathway in TGF-β family signaling. Nature 425 (2003) 577-584
17. Shi Y., and Massague J. Mechanism of TGF-β signaling from cell membrane to the nucleus. Cell 113 (2003) 685-700
18. Mishra L., Cai T., Yu P., Monga S.P., and Mishra B. Elf3 encodes a novel 200 KD β-spectrin: role in liver development. Oncogene 18 (1999) 353-364
19. Heldin C.H., Miyazono K., and Dijke T.P. TGF-β signaling from cell membrane to nucleus through Smad proteins. Nature 390 (1997) 465-471
20. Wu G., Chen Y.G., and Ozdamar B. Structural basis of Smad2 recognition by the Smad anchor for receptor activation. Science 287 (2000) 92-97
21. Mishra L., and Marshall B. Adaptor proteins and ubiquinators in TGF-β signaling. Cytokine Growth Factor Rev. 17 (2006) 75-87
22. Wrana J.L., Attisano L., Wieser R., Ventura F., and Massague J. Mechanism of activation of the TGF-β receptor. Nature 370 (1994) 341-347
23. Tang Y., Katuri V., Dillner A., Mishra B., Deng C.X., and Mishra L. Disruption of transforming growth factor-β signaling in ELF β-spectrin-deficient mice. Science 299 (2003) 574-577
24. Ohtsubo M., and Roberts J.M. Cyclin-dependent regulation of G1 in mammalian fibroblasts. Science 259 (1993) 1908-1912
25. Dobashi Y., Kudoh T., Matsumine A., Toyoshima K., and Akiyama T. Constitutive overexpression of cdk2 inhibits neuronal differentiation of rat pheochromocytoma PC12 cells. J. Biol. Chem. 270 (1995) 23031-23037
26. Dobashi Y., Goto A., Fukayama M., Abe A., and Ooi A. Overexpression of cdk4/cyclin D1, a possible mediator of apoptosis and an indicator of prognosis in human primary lung carcinoma. Int. J. Cancer 110 (2004) 532-541
27. Massague J. G1 cell-cycle control and cancer. Nature 432 (2004) 298-306
28. Matsuura I., Denissova N.G., Wang G., He D., Long J., and Liu F. Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature 430 (2004) 226-231
29. Liu F., and Matsuura I. Inhibition of Smad antiproliferative function by CDK phosphorylation. Cell Cycle 4 (2005) 63-66
30. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
31. Katuri V., Tang Y., Li C., Jogunoori W., Deng C.X., Rashid A., Sidawy A.N., Evans S., Reddy E.P., Mishra B., and Mishra L. Critical interactions between TGF-β signaling/ELF, and E-cadherin/β-catenin mediated tumor suppression. Oncogene 25 (2006) 1871-1886
32. Tang Y., Katuri V., Srinivasan R., Fogt F., Redman R., Anand G., Said A., Fishbein T., Zasloff M., Reddy E.P., Mishra B., and Mishra L. Transforming growth factor-β suppresses nonmetastatic colon cancer through Smad4 and adaptor protein ELF at an early stage of tumorigenesis. Cancer Res. 65 (2005) 4228-4237
33. Katuri V., Tang Y., Marshall B., Rashid A., Jogunoori W., Volpe E.A., Sidawy A.N., Evans S., Blay J., Gallicano G.I., Reddy E.P., Mishra L., and Mishra B. Inactivation of ELF/TGF-β signaling in human gastrointestinal cancer. Oncogene 24 (2005) 8012-8024
34. Geng Y., and Weinberg R.A. Transforming growth factor β effects on expression of G1 cyclins and cyclin-dependent protein kinases. Proc. Natl. Acad. Sci. USA 90 (1993) 10315-10319
35. Gold L.I. The role for transforming growth factor-β (TGF-β) in human cancer. Crit. Rev. Oncog. 10 (1999) 303-360
36. Laiho M., DeCaprio J.A., Ludlow J.W., Livingston D.M., and Massague J. Growth inhibition by TGF-β linked to suppression of retinoblastoma protein phosphorylation. Cell 62 (1990) 175-185
37. Datto M.B., Li Y., Panus J.F., Howe D.J., Xiong Y., and Wang X.F. Transforming growth factor β induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc. Natl. Acad. Sci. USA 92 (1995) 5545-5549
38. Gartenhaus R.B., Wang P., and Hoffmann P. Induction of the WAF1/CIP1 protein and apoptosis in human T-cell leukemia virus type I-transformed lymphocytes after treatment with adriamycin by using a p53-independent pathway. Proc. Natl. Acad. Sci. USA 93 (1996) 265-268
39. Reynisdottir I., Polyak K., Iavarone A., and Massague J. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-β. Genes Dev. 9 (1995) 1831-1845
40. INK4B through a Spl consensus site. J. Biol. Chem. 270 (1995) 26750-26753
41. Hougaard S., Norgaard P., Abrahamsen N., Moses H.L., Spang-Thomsen M., and Skovgaard Poulsen H. Inactivation of the transforming growth factor beta type II receptor in human small cell lung cancer cell lines. Br. J. Cancer 79 (1999) 1005-1011
42. Yoo Y.D., Choi J.Y., Lee S.J., Kim J.S., Min B.R., Lee Y.I., and Kang Y.K. TGF-β-induced cell-cycle arrest through the p21 (WAF1/CIP1)-G1 cyclin/CDKS-p130 pathway in gastric carcinoma cells. Int. J. Cancer 83 (1999) 512-517
43. Kim S.S., Shetty K., Katuri V., Kitisin K., Baek H.J., Tang Y., Marshall B., Johnson L., Mishra B., and Mishra L. TGF-β signaling pathway inactivation and cell cycle deregulation in the development of gastric cancer: role of the β-spectrin, ELF. Biochem. Biophys. Res. Commun. 344 (2006) 1216-1223
44. Takahashi T., Nau M.M., Chiba I., Birrer M.J., Rosenberg R.K., Vinocour M., Levitt M., Pass H., Gazdar A.F., and Minna J.D. p53: a frequent target for genetic abnormalities in lung cancer. Science 246 (1989) 491-494
45. Osada H., and Takahashi T. Genetic alterations of multiple tumor suppressors and oncogenes in the carcinogenesis and progression of lung cancer. Oncogene 21 (2002) 7421-7434